North China Pharmaceutical: On April 3rd, short selling of 40.6k shares, with a margin and securities lending balance of 241 million yuan.

Securities Star news, on April 3, North China Pharmaceutical (600812) purchased 24.18M yuan via margin financing, repaid 28.29M yuan via margin financing, net sold 4.11M yuan via margin financing, and had a financing balance of 239 million yuan.

Regarding securities lending, on the day, securities lending sold 40.6 thousand shares, repaid 1,100.0 shares, had a net securities lending sale of 39.5 thousand shares, and had remaining securities lending volume of 346.9 thousand shares.

The balance of margin financing and securities lending was 241 million yuan, down 1.62% from the previous day.

Quick Knowledge

Margin financing and securities lending: At present, individual investors participating in margin financing and securities lending mainly need to meet two conditions: 1) having engaged in securities trading for at least 6 months; 2) the account’s assets meet the requirement that the average daily assets over the past 20 trading days are 500k. Margin financing and securities lending underlying assets: The SSE will expand the number of main-board underlying stocks from the current 800 to 1,000, and the SZSE will expand the number of underlying stocks other than registered-share system stocks from the current 800 to 1,200.

The above content is compiled by Securities Star from publicly available information and generated by an AI algorithm (licensing number: 310104345710301240019), and does not constitute investment advice.